Low-dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - A randomized, controlled trial

European Journal of Haematology

Volumn 72, Issue 5, 2004, Pages 342-347

  Subirà, Maricel ^a   Martino, Rodrigo ^a,d   Gómez, Lucia ^b   Martí, Josep María ^c   Estany, Cristina ^c   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Department of Internal Medicine   (Spain)

^c HOSPITAL MÚTUA DE TERRASSA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

ABLC; Amphotericin B; Antifungal therapy; Hematologic malignancy; Neutropenic fever

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DYSPNEA; EMPIRICISM; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; INCIDENCE; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VOMITING;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HEPATITIS, TOXIC; HUMANS; HYPOKALEMIA; IMMUNOCOMPROMISED HOST; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; TREATMENT OUTCOME;

EID: 1942436895     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00239.x     Document Type: Article

References (20)

1. PIZZO PA, ROBICHAUD KJ, GILL FA, WITEBSKY FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-111.
2. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-672.
3. GALLIS HA, DREW RH, PICKARD WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
4. HIEMENZ JW, WALSH TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22 (Suppl. 2): S133-S144.
5. LINDEN P, LEE L, WALSCH TJ. Retrospective analysis of the dosage of ABLC for the treatment of invasive fungal infections. Pharmacotherapy 1999;19:1261-1268.
6. ROGERS J, CONWAY A. Tolerability of low dose amphotericin B lipid complex (Abelcet®) for the treatment of pyrexia of unknown origin (PUO) in neutropenic cancer patients [Abstract no. 493]. Bone Marrow Transplant 1998, 21 (Suppl. 1): S143.
7. COOK G, FRANKLIN IM. Adverse drug reactions associated with the administration of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1999, 23:1325-1326.
8. SUBIRÀ M, MARTINO R, SUREDA A, et al. Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. Methods Find Exp Clin Pharmacol 2001;23:505-510.
9. CAGNONI PJ, WALSH TJ, PENDERGAST MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-2483.
10. ASCIOGLU S, REX JH, de PAUW B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
11. ANAISSIE EJ, WHITE MH, OZUN O. Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomised, multicenter trial. San Francisco, CA, 35th ICAAC 1995; Abstract LM21.
12. SHARKEY PK, GRAYBILL JR, JOHNSON ES, et al. Amphotericin B lipid complex compared to amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321.
13. WINGARD J, WHITE MH, ANAISSIE E, RAFFALLI J, GOODMAN J, ARRIETA A. A randomised, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-1163.
14. FLEMING RV, KANTARJIAN HM, HUSNI R, et al. Comparison of amphotericin B lipid complex vs ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-520.
15. MYINT H, HALL R, BOLAM S, KYI AA, WINN R. Preemptive therapy with low dose amphotericin B lipid complex (Abelcet) prevents recurrence of fungal pneumonia in immunocompromised patients. Blood 1998;92 (Suppl. 1):336b.
16. PRENTICE HG, HANN IM, HERBRECHT R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718.
17. WALSH TJ, FINBERG RW, ARNDT C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-771.
18. WHITE MH, BOWDEN RA, SANDLER ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
19. BOOGAERTS M, WINSTON DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 2001;123:412-422.
20. WALSH TJ, PAPPAS P, WINSTON DJ, et al. Voriconazole compared with liposomal amphotericin B fpr empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234.